Everything drug pricing and policy, every day
But the details suggest that the Trump administration may struggle to get the effort off the ground
And Novo will book an extra $4 billion in revenue, citing confidence that its 340B contract pharmacy policies are safe from legal challenges
And the reality that MFN may mean poor access in Europe, not lower prices in the U.S., begins to sink in
And a new resource that makes plain the extent -- and variability -- of hospital markups on pharmaceuticals
And CMS ‘explanations’ for Medicare drug pricing suggest drugmakers and CMS didn’t see eye-to-eye in half of all ‘negotiations’
And CMS extends the deadline for its MFN-in-Medicaid program in an effort to get small- and mid-size companies on board
And STAT digs into drugmaker annual reports and finds that some MFN deals are not yet finalized
And the government takes pharma’s side in the debate over state regulation of 340B contract pharmacies
And looking at public comments on how CMS’ GLOBE and GUARD models will harm innovation
